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Abstract 
Purpose: The purpose of this study was to measure the dose distributions for different Radiation 
Oncology Physics and Engineering Services, Australia (ROPES) type eye plaques loaded with I-125 (model 
6711) seeds using GafChromic R EBT3 films, in order to verify the dose distributions in the Plaque 
SimulatorTM (PS) ophthalmic 3D treatment planning system. The brachytherapy module of RADCALC R 
was used to independently check the dose distributions calculated by PS. Correction factors were derived 
from the measured data to be used in PS to account for the effect of the stainless steel ROPES plaque 
backing on the 3D dose distribution. Methods: Using GafChromic R EBT3 films inserted in a specially 
designed Solid WaterTM eye ball phantom, dose distributions were measured three-dimensionally both 
along and perpendicular to I- 125 (model 6711) loaded ROPES eye plaque's central axis (CAX) with 2 mm 
depth increments. Each measurement was performed in full scatter conditions both with and without the 
stainless steel plaque backing attached to the eye plaque, to assess its effect on the dose distributions. 
Results were compared to the dose distributions calculated by Plaque SimulatorTM and checked 
independently with RADCALC R . Results: The EBT3 film measurements without the stainless steel 
backing were found to agree with PS and RADCALC R to within 2% and 4%, respectively, on the plaque 
CAX. Also, RADCALC R was found to agree with PS to within 2%. The CAX depth doses measured using 
EBT3 film with the stainless steel backing were observed to result in a 4% decrease relative to when the 
backing was not present. Within experimental uncertainty, the 4% decrease was found to be constant with 
depth and independent of plaque size. Using a constant dose correction factor of T = 0.96 in PS, where 
the calculated dose for the full water scattering medium is reduced by 4% in every voxel in the dose grid, 
the effect of the plaque backing was accurately modeled in the planning system. Off-axis profiles were 
also modeled in PS by taking into account the three-dimensional model of the plaque backing. 
Conclusions: The doses calculated by PS and RADCALC R for uniformly loaded ROPES plaques in full and 
uniform scattering conditions were validated by the EBT3 film measurements. The stainless steel plaque 
backing was observed to decrease the measured dose by 4%. Through the introduction of a scalar 
correction factor (0.96) in PS, the dose homogeneity effect of the stainless steel plaque backing was 
found to agree with the measured EBT3 film measurements. 
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I-125 ROPES eye plaque dosimetry: validation of a commercial 3-D ophthalmic brachytherapy 
treatment planning system and independent dose calculation software with GafChromic® EBT3 films. 
 
Joel Poder and Stéphanie Corde 
 
Department of Radiation Oncology, Prince of Wales Hospital, Randwick, NSW, Australia, 2031  
 
Purpose: The purpose of this study was to measure the dose distributions for different Radiation Oncology 
Physics and Engineering Services Australia (ROPES) type eye plaques loaded with I-125 (model 6711) 
seeds using GafChromic® EBT3 films, in order to verify the dose distributions in the Plaque SimulatorTM 
(PS) ophthalmic 3-D treatment planning system. The brachytherapy module of RADCALC® was used to 
independently check the dose distributions calculated by PS. Correction factors were derived from the 
measured data to be used in PS to account for the effect of the stainless steel ROPES plaque backing on the 
3-D dose distribution. 
Method: Using GafChromic® EBT3 films inserted in a specially designed Solid WaterTM eye ball phantom, 
dose distributions were measured three-dimensionally both along and perpendicular to I-125 (model 6711) 
loaded ROPES eye plaque’s central axis (CAX) with 2 mm depth increments. Each measurement was 
performed in full scatter conditions both with and without the stainless steel plaque backing attached to the 
eye plaque, to assess its effect on the dose distributions. Results were compared to the dose distributions 
calculated by Plaque SimulatorTM and checked independently with RADCALC®.  
Results: The EBT3 film measurements without the stainless steel backing were found to agree with PS and 
RADCALC® to within 2% and 4% respectively, on the plaque CAX. Also, RADCALC® was found to agree 
with PS to within 2%. The CAX depth doses measured using EBT3 film with the stainless steel backing were 
observed to result in a 4% decrease relative to when the backing was not present. Within experimental 
uncertainty, the 4% decrease was found to be constant with depth and independent of plaque size. Using a 
constant dose correction factor of T=0.96 in PS, where the calculated dose for the full water scattering 
medium is reduced by 4% in every voxel in the dose grid, the effect of the plaque backing was accurately 
modelled in the planning system. Off-axis profiles were also modelled in PS by taking into account the three-
dimensional model of the plaque backing.  
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Conclusion: The dose calculated by PS and RADCALC for uniformly loaded ROPES plaques in full and 
uniform scattering conditions were validated by the EBT3 film measurements. The stainless steel plaque 
backing was observed to decrease the measured dose by 4%. Through the introduction of a scalar correction 
factor (0.96) in PS, the dose homogeneity effect of the stainless steel plaque backing was found to agree with 




Choroidal melanoma is the most common primary intraocular malignancy1 and is commonly treated 
using external beam charged particle therapy or eye plaque brachytherapy. In 1985 the Collaborative Ocular 
Melanoma Study (COMS) trial2, 3 compared enucleation against a minimum of 100 Gy I-125 plaque 
radiation therapy for medium sized choroidal melanomas (2.5 – 10 mm in height and a maximum basal 
dimension of 16 mm), showing no significant difference in survival4. The COMS trial’s protocol calculated 
doses using a point source approximation and no heterogeneity correction. 
Following the publication of AAPM TG-43 report in 1995 providing a dose calculation formalism 
for Ir-192, I-125 and Pd-103 sources5 and the changes to a new primary air kerma strength calibration 
standard6, the recommended dose prescription of 100 Gy was lowered to 85 Gy. This new dose calculation 
formalism allowed for a line source approximation of the source; however the effects of the plaque backing 
and seed carrier were still ignored. A TG-43 report update was released in 2004 (TG-43U1)7 to include new 
brachytherapy sources and critically reassess some published brachytherapy dosimetry data including the I-
125 source (Amersham Health (Princeton, NJ) model 6711). Recommendations were also provided for dose 
calculation methods for episcleral plaque therapy following the COMS protocol.  
It is now well recognized that incorporating the effects of heterogeneities into the dose calculation is 
essential and can result in a significant change in the dose to the tumour and sensitive structures in episcleral 
plaque therapy. This has been an area of extensive research in recent years, using both experimental8-11 and 
Monte Carlo methods1, 12-14. This is reflected in the recent release of the AAPM TG-129 report15, which gives  




The TG-129 report focuses on the standard COMS design eye plaques, examining heterogeneity 
effects specific to this plaque design. The standard COMS plaque design consists of a gold-alloy backing 
(density = 15.8 g/cm3) and a Silastic seed carrier insert (density 1.12 g/cm3, Zeff = 11). ROPES type eye 
plaques however, consist of a stainless steel backing (density = 7.912 g/cm3) and an acrylic seed carrier 
insert (density 1.069 g/cm3, Zeff = 6.5)
16. For both the COMS and ROPES plaques the seed insert has a radius 
of curvature of ~12 mm in order to conform to the external sclera and offset the seeds by 1 mm from the 
sclera. Due to differences in atomic number and density of materials used in the construction of the ROPES 
and COMS type eye plaques, the effect of these materials on the dose distributions produced by the plaques 
is expected to be dissimilar. For example, the effective atomic number of the acrylic insert in the ROPES 
type eye plaques is much closer to the atomic number of water (Zeff ~7.4)
13, than that of the Silastic insert in 
the COMS type plaques. 
Thomson and Rogers reported in 2010, that the dose calculations are specific to not only the seed 
model, but also the type of eye plaque1. Using the BrachyDose Monte Carlo code, they calculated dose 
distributions for six Pd-103 and I-125 seed models. Differences in dose reduction relative to homogeneous 
water assumption varied between seed models and plaque types of order 2%. Whilst the dosimetric studies of 
model 6711 I-125 seeds are extensive, many of these are limited to the study of the seeds in conjunction with 
COMS plaques1, 8, 13, 14. To date, one group has published a Monte Carlo study of the dose distributions 
produced by ROPES type eye plaques with model 6711 I-125 seeds17, and another using two models of Pd-
103 seeds16.  
Granero et al.17 performed Monte Carlo simulations both with and without the acrylic seed carrier to 
assess its effect on the dose distribution for the 15 mm diameter ROPES plaque. Saidi et al.16 also performed 
Monte Carlo simulations of the 15 mm diameter ROPES plaque. Using version 5 of MCNP, the effect of the 
stainless steel backing and acrylic carrier on the dose distributions produced by plaques loaded with 
Theragenics200 and IR06 Pd-103 seeds was assessed.  
Whilst Monte Carlo methods are increasingly being used in the study of low energy photon emitting 
brachytherapy sources, experimental studies are still of value in order to address the variability that 
represents the clinical environment7. The low energy of the photons emitted by the I-125 seed makes 
experimental measurements of the dose distributions emitted by the seed particularly difficult. The steep 
dose gradients result in the need for the detector being used to have a relatively small active volume. The 
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detector also needs to be water-equivalent in the energy range of interest, or have a well-characterized energy 
response function. 
Previous attempts to measure dose distributions produced by 10 mm and 15 mm diameter ROPES 
plaques using customized PRESAGEm 3-D type dosimeters18 lacked accurate calibration of the fluorescence 
intensity measurements to dose. The small size of the customized gels prevented high resolution 3-D 
measurements but still demonstrated an effect of the stainless steel backing on the ROPES plaque CAX dose. 
Radiochromic film dosimetry has recently been established as a reliable method in measuring dose 
distributions produced by COMS type eye plaques loaded with various I-125 seed models10, 19-22. Acar22 and 
Acar et al.19 have used GafChromic® EBT film in a polystyrene eye phantom to measure absolute doses 
along the plaque CAX and in off-axis directions at depths of 5 and 12 mm for four types of COMS plaques 
loaded with model I25.S16 I-125 seeds. Krintz et al.10 measured relative dose distributions from COMS eye 
plaques uniformly loaded with model 6711 I-125 seeds in a Solid WaterTM phantom using GafChromic 
model MD55-2 films. They found a 15% average decrease of the relative off-axis doses as measured by the 
films compared to doses calculated by PS. 
The Plaque SimulatorTM program is a dedicated eye plaque treatment planning system. The software 
supports dose calculations for a variety of radioactive nuclides and seed models. The dose calculations are 
performed in 3-D and are visualized on retinal diagrams and sagittal cross-sections23. The algorithm is based 
on the AAPM TG-43 dose calculation formalism, using the superposition of contributions to the total dose 
from individual seeds24. The software also incorporates additional features that could model three-
dimensionally the effect of the plaque backing material and ray-trace the path of primary radiation between 
the calculation point and a linear radiation source. The three-dimensional model of the plaque backing 
material uses an algorithm that attenuates primary radiation which passes through the shape of the plaque 
backing, whilst ignoring all secondary scatter effects. The software accounts for collimation and scatter 
effects of the primary radiation emitted from the radioactive seeds by the metal plaque backing and 
transmission by the seed carrier through the carrier (or dose correction) factor24. These effects are well 
defined in COMS plaques25, however corrections for ROPES type eye plaques are yet to be adequately 
defined, and there are no corrections available for ROPES eye plaques in PS. 
RADCALC® v6.1.3.2 (Lifeline Software, Inc. USA) is a versatile program designed to independently 
check radiotherapy dose calculations. The brachytherapy module calculates doses to points of interest for 
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various brachytherapy sources whose data and model/approximation are user defined. The brachytherapy 
module of the RADCALC® program has previously been shown by Dempsey26 as being a useful tool for 
independent checking of dwell times in high dose rate brachytherapy applications. The current study aims to 
extend this application and use RADCALC® as an independent checking program for eye plaque 
brachytherapy implant times as calculated by PS. 
In this work, the absolute doses for a number of ROPES type eye plaques loaded with uniform 
activity model 6711 I-125 seeds were calculated by both PS and RADCALC®. These calculations were 
experimentally verified by performing absolute dose measurements with GafChromic® EBT3 film in a 
specially designed Solid WaterTM eye phantom. These measurements were performed both with and without 
the stainless steel plaque backing in order to quantify the effect of the plaque backing in three-dimensions. 
Using the results of the film measurements, correction factors were used to model the effect of the ROPES 
plaque backing proposed in the PS software. 
 
II. MATERIALS AND METHODS 
II.A. I-125 seed and ROPES eye plaques 
 
The ROPES eye plaques (Figure 1) consist of an acrylic carrier with slots for the I-125 seeds 
combined with a stainless steel backing shield to place the acrylic insert in. Available nominal diameters are 
10, 15 and 18 mm with 4, 9 or 10, and 14 seeds, respectively. The 15 mm diameter plaque with the 9 seed 
insert is used for tumours close to the optic nerve. The stainless steel backing and the acrylic insert are 
portion of a semi-spherical shell and offset the radioactive seeds by approximately 1 mm from the outer 
sclera17. 
Figure 1 shows the configuration of the seeds within each of the four different ROPES eye plaques 
used in this study. The angle φ defines the angle between the positive x axis and the projection on the x-y 
plane of the line passing through the seed centre (as shown in Figure 1b). The seed coordinates for each eye 
plaque are listed in Table I. Like the TG-129 report and COMS, the coordinate system origin is defined as 
1 mm away from the inner concave surface at the rotational centre of the acrylic insert, with the positive z 
axis pointing into the eye. The x and y axes are defined as shown in Figure 1. The seed coordinates are based 
on those defined in Plaque SimulatorTM (v 5.5.0) that were found to agree with engineering drawings 
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provided by the manufacturer to within 0.04 mm, with the exception of the 10 mm plaque which is a non-
standard prototype ROPES eye plaque27. 
 
FIG. 1. Seed diagram for a) the 10 mm ROPES plaque, b) the 15 mm ROPES plaque, c) the 15 mm notched 
ROPES plaque, d) the 18 mm ROPES plaque. The views are from the concave aspect of the acrylic seed 




TABLE I. Seed coordinates (mm) for the 10 mm, 15 mm, 15 mm notched, and 18 mm diameter ROPES eye 
plaques. Position of the seed numbers are shown in Figure 1. The coordinate system origin is defined as 
1 mm away from the inner concave surface at the rotational centre of the acrylic insert. The angle φ is the 
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angle between the positive x axis and the projection on the x-y plane from the origin to the seed centre is 
indicated in Figure 1. The seed physical length is taken as 4.5 mm.  
Seed 
# 
Seed centre  
coordinates 
 
Seed end coordinates Angle  
φ (°) 




1 -3.69 0.00 -1.99 -3.69 2.25 -1.99 -3.69 -2.25 -1.99 90.00 
2 0.00 -3.69 -1.99  -2.25 -3.69 -1.99 2.25 -3.69 -1.99 180.00 
3 3.69 0.00 -1.99  3.69 -2.25 -1.99 3.69 2.25 -1.99 270.00 




1 -1.97 1.14 -1.9  -0.85 3.09 -1.9 -3.10 -0.81 -1.9 60.00 
2 0.00 -2.27 -1.9  -2.25 -2.27 -1.9 2.25 -2.27 -1.9 180.00 
3 1.97 1.14 -1.9  3.10 -0.81 -1.9 0.85 3.09 -1.9 300.00 
4 0.00 5.95 -0.67  2.25 5.95 -0.67 -2.25 5.95 -0.67 0.00 
5 -4.65 3.71 -0.67  -3.25 5.47 -0.67 -6.05 1.95 -0.67 51.43 
6 -5.80 -1.32 -0.67  -6.30 0.87 -0.67 -5.30 -3.52 -0.67 102.86 
7 -2.58 -5.36 -0.67  -4.61 -4.38 -0.67 -0.55 -6.33 -0.67 154.29 
8 2.58 -5.36 -0.67  0.55 -6.33 -0.67 4.61 -4.38 -0.67 205.71 
9 5.80 -1.32 -0.67  5.30 -3.52 -0.67 6.30 0.87 -0.67 257.14 




1 -1.97 1.14 -1.9  -0.85 3.09 -1.9 -3.10 -0.81 -1.9 60.00 
2 1.97 1.14 -1.9  3.10 -0.81 -1.9 0.85 3.09 -1.9 300.00 
3 0.00 5.95 -0.67  2.25 5.95 -0.67 -2.25 5.95 -0.67 0.00 
4 -4.65 3.71 -0.67  -3.25 5.47 -0.67 -6.05 1.95 -0.67 51.43 
5 -5.80 -1.32 -0.67  -6.30 0.87 -0.67 -5.30 -3.52 -0.67 102.86 
6 -2.77 -4.18 -1.10  -0.75 -3.47 -1.81 -4.78 -4.89 -0.40 146.50 
7 2.77 -4.18 -1.10  0.75 -3.47 -1.81 4.78 -4.89 -0.40 213.50 
8 5.80 -1.32 -0.67  5.30 -3.52 -0.67 6.30 0.87 -0.67 257.14 






1 -2.32 3.19 -1.49  -0.50 4.51 -1.49 -4.14 1.86 -1.49 36.00 
2 -3.75 -1.22 -1.49  -4.44 0.92 -1.49 -3.05 -3.36 -1.49 108.00 
3 0.00 -3.94 -1.49  -2.25 -3.94 -1.49 2.25 -3.94 -1.49 180.00 
4 3.75 -1.22 -1.49  3.05 -3.36 -1.49 4.44 0.92 -1.49 252.00 
5 2.32 3.19 -1.49  4.14 1.86 -1.49 0.50 4.51 -1.49 324.00 
6 0.00 7.61 0.34  2.25 7.61 0.34 -2.25 7.61 0.34 0.00 
7 -4.89 5.83 0.34  -3.17 7.27 0.34 -6.61 4.38 0.34 40.00 
8 -7.49 1.32 0.34  -7.10 3.54 0.34 -7.88 -0.89 0.34 80.00 
9 -6.59 -3.80 0.34  -7.71 -1.86 0.34 -5.46 -5.75 0.34 120.00 
10 -2.60 -7.15 0.34  -4.72 -6.38 0.34 -0.49 -7.92 0.34 160.00 
11 2.60 -7.15 0.34  0.49 -7.92 0.34 4.72 -6.38 0.34 200.00 
12 6.59 -3.80 0.34  5.46 -5.75 0.34 7.71 -1.86 0.34 240.00 
13 7.49 1.32 0.34  7.88 -0.89 0.34 7.10 3.54 0.34 280.00 
14 4.89 5.83 0.34  6.61 4.38 0.34 3.17 7.27 0.34 320.00 
* The 10 mm plaque is a non-standard prototype ROPES plaque27. 
 
The Amersham Health (Princeton, NJ) model 6711 I-125 seed contains a cylindrically shaped silver 
rod on which I-125 has been coated onto the surface encased in a cylindrically symmetric titanium shell. It 
emits photons with a weighted mean energy of 28.37 keV, and has a physical length of 4.5 mm28. 
 
II.B. GafChromic® EBT3 film 
 
The radiochromic films used in this study were GafChromic® EBT3 films with lot numbers 
A09231103 and A02061301 (Ashland Inc., Wayne, NJ, USA). The EBT3 film is comprised of an active 
layer containing the active component, marker dye, stabilizers and other additives that give the film a 
uniform response to high-energy and low-energy photons29, 30. The active layer is nominally 27 µm thick and 
is sandwiched between two 120 µm transparent polyester substrates. The yellow marker dye in the active 
layer reduces UV/light sensitivity and the polyester substrate has a special surface coating that maintains a 
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gap between the film surface and the glass window of a flatbed scanner in order to reduce the formation of 
Newton’s Rings29. The films were handled according to the recommendations given in the AAPM TG 55 
Report31. 
 
II.B.1 Film calibration 
 
Calibration films were cut into 5x5 cm2 square pieces and placed at the surface of a 30x30x5 cm3 
slab of Gammex RMI 457 Solid WaterTM (Gammex Inc. Wisconsin, USA) in an orientation perpendicular to 
the beam CAX of a Pantak Therapax DXT 300 orthovoltage machine. Multiple sets of film were exposed to 
a 75 kVp, 30 mA beam (with inherent filtration of 2.0 mm Be, added filtration of 2.40 mm Al and HVL of 
2.63 mm Al) to dose levels ranging from 0 to 2 Gy in 0.2 Gy increments at 50 cm focus to source distance. 
Each film was irradiated, one at a time, centred in 10x10 cm2 field with the applicator abutting the film and 
phantom surface. The energy of the beam was chosen because the effective energy of the beam was 
evaluated using the SpekCalc simulation software32 to be 30.0 keV, which is comparable to the 28.37 keV 
weighted mean energy of the model 6711 I-125 seed. Brown et al.30 measured the relative sensitivity of 
EBT3 film in the energy range of 25 to 35 keV using synchrotron-produced monochromatic x-ray beams. 
The study showed that the sensitivity (net optical density (NOD) per unit dose) varied by less than 2% within 
the x-rays energy range of 25 – 35 keV. The output of the orthovoltage machine was calibrated using the 
IPEMB code of practice33. 
 
II.B.2. Single seed measurements 
 
To confirm the correct calibration of the films, multiple pieces of film were irradiated in a Solid 
WaterTM phantom at two distances away from the centre of a single model 6711 I-125 seed along its 
transverse axis (Figure 2). A groove was machined into a slab of Solid WaterTM in the shape of the model 
6711 I-125 seed and pieces of EBT3 film placed horizontally between slabs of Solid WaterTM, one at a time. 
Additional pieces of Solid WaterTM were placed below the seed and above the film in order to maintain full 
scatter conditions.  
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Measured doses were corrected using a Solid WaterTM correction factor of 1.038 to account for the 
non perfect water equivalence of the Solid WaterTM at these photon energies. This value is an average of the 
values published by Williamson34, Meigooni et al.35 and Tailor et al.36 who found Solid WaterTM correction 
factors of 1.043, 1.032 and 1.040 respectively. As such, an uncertainty of 0.6% in the Solid WaterTM 
correction factor has been used in this study. 
The air-kerma strength7 of the seed used was 8.11 U (cGy.cm2.h-1), and the EBT3 films were 
irradiated for a period of 1 hour. Measured doses were then compared against the TG-43U1 calculated doses 
from PS and RADCALC® for the given exposure time at depths of 2.51 and 4.51 mm (centre of seed to 
centre of film distance). All depths were measured using calibrated vernier scale callipers with a 
measurement precision of 0.01 mm. Also, as shown by Dolan et al.28 the cylindrically shaped silver rod is 
free to move around within the titanium capsule of the 6711 seed by up to 0.08 mm in the seed transverse 
direction. The sum of these uncertainties gives the total combined uncertainty in depth approximation of 





FIG. 2. Schematic diagram (not to scale) showing the configuration of the EBT3 film and I-125 seed in a 
Solid WaterTM phantom for the single seed measurements. The reported distance is from the centre of the 
seed to the centre of the EBT3 film.  
 
 
II.B.3. Eye phantom irradiations 
 
Experimental films were cut into 5x5 cm2 square pieces and placed in a specially designed Solid 
WaterTM eye phantom (Figure 3). The eye phantom was shaped into a sphere of 24 mm diameter and 
dissected into pieces of 2.00 mm thickness. The sphere could then be arranged to allow measurements with 
EBT3 film in increments of 2.00 mm depth with the film positioned orthogonal to the plaque CAX. A 
30x30x5 cm3 slab of Solid WaterTM was placed beyond the EBT3 film to maintain full scatter conditions. 
Pieces of Solid WaterTM were machined in order to fit over individual plaques, and provide full backscatter 
during the measurements. 
ROPES eye plaques were loaded with uniform activity model 6711 I-125 seeds. EBT3 films were 
placed sequentially at depths of 1, 3, 5, 7 and 9 mm orthogonal to the plaque’s CAX for each type of ROPES 
plaque. Three separate EBT3 films were used for each plaque at each measurement depth (60 in total). The 
exposure times were calculated in PS to deliver a total dose of 2 Gy to 2 mm depth on the plaque CAX. Seed 




FIG. 3. Schematic diagram (not to scale) showing the experimental arrangement of the uniformly loaded 
ROPES eye plaque measurements. The reported distance of 5.11 mm is from the plaque origin (as described 
in Table I) to the centre of the EBT3 film. The 15 mm diameter ROPES plaque is shown, including the 
collimating lip of the plaque backing.  
 
 
II.B.4. Film analysis & scanning 
 
EBT3 films were scanned both prior to and 24 hours after exposure in an Epson 10000XL flatbed 
scanner (SEIKO Epson Co, Japan), in a jig to ensure sub-pixel reproducible positioning of the film within the 
scanning area. Film scans prior to exposure were obtained to measure the optical density of the background 
image. The post-exposure scans allowed the calculation of the net optical density (NOD) after which the 
latent image had stabilized37 by subtracting the background value from the optical density (OD) on a per-
pixel basis.  
Each film was scanned in transmission mode using 48 bit RGB with a scanner resolution of 75 dpi 
(0.34 mm pixel size). All film pieces were marked in order to maintain the same orientation throughout 
scanning and measurement thereby eliminating polarisation effects38. The films were positioned at the centre 
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of the flatbed scanner to avoid off-axis scanner non-uniformity39. ImageJ software v1.42q (National 
Institutes of Health, Maryland, USA) was used to analyse films and measure pixel values for the pre-
irradiation and post-irradiation scans. For calibration films, a 5x5 mm2 region of interest (ROI) was used to 
measure the pre-irradiation and post-irradiation pixel values. Films used to measure the ROPES plaque dose 
distributions were analysed on a pixel by pixel basis. The pixel values measured from the red channel of the 
scanner were used to calculate the NOD for each film piece and these were converted to absorbed dose to 
water in water for I-125 ( , in Gy) using the following formula: 
, , , 	 ,
,  
where 
,  is the NOD measurement of the films irradiated with I-125 in Solid Water TM; 
,  is the energy dependence of the films between I-125 and 75kVp (value taken to be 1); 
,  is the films NOD-to-dose to water calibration curve at 75kVp (Gy); 
,  is the solid water to water correction factor, taken as 1.038 in this study. 
 
II.C. Dose calculations in Plaque SimulatorTM and RADCALC® 
 
The line-source approximation for the geometry function and 2-D anisotropy corrections were used 
for the I-125 (model 6711) sources in both Plaque SimulatorTM (v5.5.0) and RADCALC® (v6.1.3.2) and lead 
to single seed dose comparison of difference less than 1% at distances up to 1cm from the seed centre18. 
The plaques were loaded with model 6711 I-125 seeds and treatment times calculated in PS to 
deliver 2 Gy to a depth of 2 mm without accounting for any plaque heterogeneity effects. In RADCALC®, 
the 3-D I-125 seeds geometries were defined for every ROPES eye plaque type available, as per the 
coordinates in Table I. The corresponding PS treatment times were corrected to take into account that 
RADCALC® (v6.1.3.2) does not account for the decay of the sources during treatment. CAX depth dose and 
off-axis dose distributions were then compared for each of the ROPES eye plaques under full homogeneous 
conditions, as well as to measurements made with the EBT3 film at depths of 1, 3, 5, 7 and 9 mm without the 
stainless steel plaque backing. A repeat of these measurements with the stainless steel backing allowed the 
calculation of the dose correction factor to be implemented in PS to account for the collimation and scatter 
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effects caused by the stainless steel backing. The three-dimensional shape of the plaque backing was 
modeled independently in PS according to the manufacturer’s engineering drawings and depth doses and off 
axis profiles were recalculated with PS. 
 
II.D. Uncertainty Analysis 
 
The calculation of the total uncertainty in the film measurements follows recommendations given in the joint 
AAPM/ESTRO TG 138 Report40. Components of measurement uncertainty may be classified into random 
uncertainties evaluated by statistical methods (type A) and those evaluated by other means, which are 
systematic (type B). The contributions to the total uncertainty in the calibration film measurements include a 
0.8% type A uncertainty from the standard deviation of OD value within the ROI for one calibration film, a 
3.5% type A uncertainty from the standard deviation of OD in repeated scanning of the same calibration 
film, 0.74% type B uncertainty from the fit of the curve used to convert NOD to dose and a 2.5% type B 
uncertainty in the calibration of the x-ray beam used to calibrate the films. The total uncertainty in 
conversion from NOD to dose is stated as 4.4% (k = 1). This uncertainty in conversion from NOD to dose 
becomes a Type B uncertainty for eye phantom measurements. 
The total uncertainty of the single seed verification measurements with three repeated measurements 
at each depth was estimated as 6.1%. The single type A contribution to the total uncertainty is the standard 
deviation of the average value of NOD from repetitive measurements. Type B contributions to the total 
uncertainty of the single seed measurements include, conversion of NOD to dose, uncertainty in the seed’s 
air-kerma strength, uncertainty in the Solid WaterTM correction factor used34, and seed-film positioning 
uncertainty.   
Table II shows the estimation of the total uncertainty in the eye phantom measurements. The 
dosimetric effect of the positional uncertainty has been averaged over all central axis depths and plaque 
types. The eye phantom measurements total uncertainties are an average of 5.4% for CAX measurements and 
6.7% for off-axis values. 
 
TABLE II. Uncertainty in eye phantom measurements. 
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 Type A Type B 
Uncertainty in NOD from 3 data points (3 repetitive 
measurements). 
2.5% (CAX)  
Uncertainty in NOD from 3 data points (3 repetitive 
measurements). 
4.7% (off-axis)  
Uncertainty in conversion from NOD to dose  4.4% 
Uncertainty in seed’s air-kerma strength, SK, (incorporating 
uncertainty in half-life) 
 1.6% 
Uncertainty in Solid WaterTM correction factor  0.6% 
Average positioning uncertainty, ud = 0.09 mm (dose change 
between d and d ± ud) 
 0.6% 
Total plaque CAX measurement uncertainty 5.4% 
Total plaque off-axis measurement uncertainty 6.7% 
 
III. RESULTS 
 III.A. Gafchromic® EBT3 film and single 125I seed (model 6711) 
 
The single seed EBT3 film measurements were compared to calculated doses from PS and 
RADCALC® for a given exposure time at two depths. PS and RADCALC® had previously been shown to 
agree with hand calculations using TG-43U1 data to within 1% for a single model 6711 I-125 seed18.  
Agreement between the single seed EBT3 film measurements with calculated doses from PS and 
RADCALC® were within 1.5%. The results are summarised in Table III.  
 
TABLE III. Single seed EBT3 film measured dose comparison with calculated doses. 
Depth (mm) EBT3 Film (Gy) PS (Gy) RADCALC® (Gy) 
2.51 1.21 ± 0.07 1.224 1.220 




 III.B. Gafchromic® EBT3 film and uniformly loaded ROPES eye plaques 
  III.B.1. Central axis depth dose 
 
The CAX depth dose distributions for uniformly loaded ROPES eye plaques, as measured using 
EBT3 film are presented in Table IV. Measured CAX depth doses are given without the plaque stainless 
steel backing as compared with those calculated by both PS and RADCALC®. As shown in Table II, the 
average total uncertainty in the CAX depth dose measurements was 5.4%.  
Using the data in Table IV, it was found that the average reduction in dose on CAX due to the 
stainless steel backing across all of the ROPES plaques at each depth of measurement was 0.96 ± 0.01 (k=1). 
This value was then entered into PS as a single dose correction factor T = 0.96 and the dose to each point of 
measurement recalculated. This dose is shown in Table IV as PS Hetero, and is observed to have good 
agreement with the film measurements in which the stainless steel backing was left on. Agreement is also 
observed between the film measurements without the stainless steel backing and the full homogeneous water 
calculations (PS Homo and RADCALC®), this indicates that the acrylic seed carrier has a negligible effect 
on the CAX depth dose. 
 
TABLE IV. EBT3 film measured and calculated CAX depth dose (Gy) for uniformly loaded ROPES eye 
plaques. The measurement depths are given from the origin of the eye plaque to the centre of the EBT3 film, 
as shown in Figure 3. 










10 mm 1.11 1.943 1.943 1.95 ± 0.15 1.87 ± 0.15 1.865 
 3.11 1.133 1.137 1.14 ± 0.06 1.08 ± 0.06 1.088 
 5.11 0.689 0.695 0.68 ± 0.04 0.66 ± 0.04 0.661 
 7.11 0.446 0.450 0.45 ± 0.02 0.43 ± 0.02 0.428 
 9.11 0.304 0.307 0.30 ± 0.02 0.29 ± 0.02 0.292 
15 mm 1.11 1.944 1.944 1.92 ± 0.14 1.83 ± 0.14 1.866 
 3.11 1.194 1.198 1.17 ± 0.05 1.12 ± 0.06 1.146 
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 5.11 0.771 0.777 0.78 ± 0.04 0.75 ± 0.04 0.740 
 7.11 0.517 0.521 0.51 ± 0.02 0.49 ± 0.02 0.496 
 9.11 0.360 0.362 0.36 ± 0.02 0.35 ± 0.02 0.346 
15 mmN 1.11 1.949 1.949 1.93 ± 0.14 1.85 ± 0.14 1.871 
 3.11 1.236 1.240 1.23 ± 0.06 1.17 ± 0.06 1.187 
 5.11 0.805 0.816 0.80 ± 0.04 0.77 ± 0.04 0.773 
 7.11 0.541 0.545 0.54 ± 0.02 0.52 ± 0.02 0.519 
 9.11 0.376 0.383 0.37 ± 0.02 0.36 ± 0.02 0.361 
18 mm 1.11 1.967 1.970 1.93 ± 0.14 1.89 ± 0.14 1.888 
 3.11 1.418 1.429 1.41 ± 0.07 1.36 ± 0.07 1.361 
 5.11 1.003 1.020 1.01 ± 0.05 0.97 ± 0.05 0.963 
 7.11 0.714 0.729 0.70 ± 0.03 0.68 ± 0.03 0.685 
 9.11 0.516 0.527 0.51 ± 0.02 0.48 ± 0.02 0.495 
  
Using the results from Table IV, along with the heterogeneity correction determined for PS, a table 
of CAX dose values for ROPES plaques loaded with uniform activity model 6711 I-125 seeds was calculated 
without and with the steel backing correction, and is shown in Table V. The table displays the CAX depth 
doses for the eye plaques with seed coordinates given in Table I, with the dose normalised to 85 Gy at 4 mm 
depth for the homogeneous dose calculation. 
 
TABLE V. CAX dose values (Gy) of the homogeneous and heterogeneous calculations for the four ROPES 
plaques investigated in this study, with the homogeneous dose normalized to 85 Gy at 4 mm depth for each 
plaque. Data are for the ROPES plaques uniformly loaded with model 6711 I-125 seeds and the depths are 
given from the origin of the eye plaque as shown in Figure 3. 
Depth 
(mm) 
PS Homo  PS Hetero 
10 mm 15 mm 15 mmN 18 mm  10 mm 15 mm 15 mmN 18 mm 
-1 286.50 288.55 257.79 169.39  275.04 277.01 247.48 162.61 
0 239.46 227.37 211.00 158.54  229.88 218.28 202.56 152.20 
18 
 
1 187.61 173.89 167.05 139.80  180.11 166.93 160.37 134.21 
2 143.56 134.95 132.53 119.58  137.82 129.55 127.23 114.80 
3 109.82 106.46 105.80 101.02  105.43 102.20 101.57 96.98 
4 85.00 85.00 85.00 85.00  81.60 81.60 81.60 81.60 
5 66.75 68.59 68.80 71.50  64.08 65.85 66.05 68.64 
6 53.21 55.84 56.10 60.21  51.08 53.61 53.86 57.80 
7 43.04 45.88 46.14 50.84  41.32 44.04 44.29 48.81 
8 35.29 38.07 38.29 43.10  33.88 36.55 36.76 41.38 
9 29.29 31.85 32.04 36.68  28.12 30.58 30.76 35.21 
10 24.57 26.88 27.05 31.38  23.59 25.80 25.97 30.12 
11 20.83 22.87 23.01 26.98  20.00 21.96 22.09 25.91 
12 17.81 19.61 19.73 23.33  17.10 18.83 18.94 22.40 
13 15.34 16.92 17.02 20.27  14.73 16.24 16.34 19.50 
14 13.31 14.69 14.78 17.70  12.78 14.10 14.19 16.99 
 
III.B.3. Off-axis profiles 
 
Off-axis dose was measured at each of the 2 mm depth increments given in Table IV. Measured off-
axis dose at the most clinically relevant depth of 5.11 mm plotted against off-axis distance for each of the 
four types of ROPES plaques, are shown in Figures 4(a) to 4(d). The PS Homo curve shows the PS 
calculated dose for a full homogeneous water assumption, whereas the PS Hetero curve shows the PS 
calculated dose with the T = 0.96 dose correction factor included, as well as the three-dimensional modelling 
of the plaque backing.  
Agreement is again observed between the film measurement without the stainless steel backing and 
the dose to water calculations, verifying that the acrylic seed carrier also has a negligible effect on the dose 
off-axis as well as on the plaque CAX. The global dose correction factor of T = 0.96 is also observed to 
produce satisfactory agreement with the off-axis measured dose with the stainless steel backing left on.  
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The effect of the three-dimensional model of the plaque backing is shown in Figures 4(a), 4(b) and 
4(c) where a sharp drop in dose occurs near the plaque periphery. This is due to the collimating lip of the eye 
plaque, which consists of a cylindrical segment connected to the spherical shell of the plaque backing, as 
shown in Figure 3. The effect of the collimating lip in the three-dimensional model of the plaque was 
observed to decrease with increasing depth. In order to calculate the dose correctly in this region, it is 
therefore essential that the dimensions of the plaque backing be modelled precisely in the planning system. 
This region is of particular interest when attempting to quantify the dose received by organs at risk during 
plaque therapy. The plaque backing dimensions and compositions used in the planning system should be 
cross-checked with engineering drawings and technical data provided by the manufacturer.    
 
FIG. 4. Off axis profiles at 5.11 mm depth for the a) 10 mm ROPES plaque, b) 15 mm ROPES plaque, c) 
15 mm notched ROPES plaque, d) 18 mm ROPES plaque. Dose calculated are represented with lines and 
dose measured with symbols: RADCALC (dashed lines), PS Homo (solid line), Film without backing 
(closed square), PS Hetero (dotted line) and Film with backing (open triangle). Errors bars represent the 







The agreement between measured and calculated doses for the single seed experiments confirmed 
the accuracy of the measurement method using EBT3 film in Solid WaterTM, as well as the calibration 
method with the orthovoltage unit. 
EBT3 film measurements without the stainless steel backing have been shown to agree with full dose 
to water calculations, indicating that the acrylic seed carrier has a negligible effect on the dose compared to a 
full dose to water assumption. Granero et al.17 and Saidi et al.16 have performed Monte Carlo simulations of 
the 15 mm diameter ROPES plaque, both with and without the acrylic seed carrier to assess its effect on the 
dose distribution. It was also found in these studies that the acrylic carrier had a negligible effect on the dose 
distribution.  
Granero et al.17 also found a uniform dose reduction of 4% due to the stainless steel plaque backing 
in the Monte Carlo study for the 15 mm diameter ROPES plaque with model 6711 I-125 seeds. This is in 
agreement with the dose correction factor of T = 0.96 ± 0.01 (k=1) found using the EBT3 film measurements 
in this study. With a heterogeneity correction factor T = 0.96 enabled in PS, the material heterogeneity effect 
of the stainless steel backing could be modelled to match the EBT3 film measurements accurately in three 
dimensions, within the uncertainty of the measured data to a depth of 10 mm.   
Saidi et al.16 found a depth dependent dose correction factor in their Monte Carlo study of two 
models of Pd-103 seeds in a 15 mm diameter ROPES plaque. A reduction of 4% due to the stainless steel 
backing was observed at 2 mm depth, and this reduction increased to approximately 9% at 5 mm depth. 
When including the three-dimensional model of the plaque backing in PS a sharp drop in dose 
occurs near the plaque periphery due to the effect of the plaque collimating lip. This effect was also observed 
in off-axis profile measurements with the stainless steel backing left on. It is in this penumbral region where 
largest deviations were observed between the measured and predicted doses. These dose differences may be 
attributed to uncertainties in the film measurements due to positioning uncertainties, or the algorithm used in 
PS to account for the collimating lip19. The effect was also observed by Acar et al.19 in their measurements of 
the dose distribution produced by COMS plaques using EBT film. Deviations of up to 17% at 5 mm depth 
and 9% at 12 mm depth occurred between their film measurements and the heterogeneous PS calculation.   
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Accurate dose calculations are necessary in order to correctly predict the dose to critical structures. It 
is therefore necessary to model the effect of the eye plaque accurately in three dimensions. However, as 
noted in AAPM TG-129 report15, standardized methods of dose calculation allow multi-institutional analysis 
of treatment efficacy and side effects. Therefore, the report recommends calculation of both homogeneous 
(full water medium) and heterogeneous (taking into account the effects of plaque materials) dose 
distributions. Homogeneous TG-43 dose calculations allow for a comparison of the prescribed dose with 
patients previously treated at the institution, as well as with other institutions who have historically used the 
TG-43 dose calculation formalism. Heterogeneous dose calculations allow for a more accurate prediction of 
the dose delivered to the tumour and surrounding critical structures. The report also included a table of 
central-axis dose values for fully loaded COMS eye plaques with model 6711 I-125 seeds for both the 
homogeneous and heterogeneous dose calculations. A corresponding table for ROPES plaques loaded with 
model 6711 I-125 seeds is included as Table V. 
The TG-129 report also recommends an independent check of the dose calculation using either a 
spreadsheet or third party software. The brachytherapy module of the RADCALC® independent checking 
program has been shown in this study to be appropriate for this purpose and can be used for 3-D dose 
verification. TG-129 recommends a tolerance of ± 2% on the CAX, the maximum difference observed on the 
CAX in this study between RADCALC® and PS was within this tolerance. 
The analysis performed in this study, and that of the TG-129 report, do not consider the effect of 
tissue heterogeneities within and surrounding the eye. These tissue heterogeneities are likely to further 
modify the dose distributions from what is observed in conventional TG-43 dose calculations. For example, 
Thomson et al. calculated dose to a number of different eye tissues for I-125 and Pd-103 seeds in various 
COMS type eye plaques and found differences of up to 9% compared to dose to water calculations13.  
Modern brachytherapy planning systems are introducing model based dose calculation algorithms that will 
take these tissue heterogeneities into account, and any change in prescribed dose must be carefully examined 
before introduction of the model based system into the clinical environment. The AAPM/ESTRO/ABS/ABG 






Dose distributions produced by ROPES type eye plaques loaded with model 6711 I-125 seeds and 
calculated with Plaque SimulatorTM without or with correction for the stainless steel backing have been 
successfully verified with Gafchromic® EBT3 film measurements in a Solid WaterTM eye phantom. The 
method of dosimetric analysis could be useful in confirming dose distributions predicted by new model 
based brachytherapy dose calculation algorithms. Measurements performed both on the CAX and off-axis in 
the absence of the plaque stainless steel backing showed good agreement with homogeneous water dose 
calculations, indicating that the acrylic seed carrier in ROPES plaques has a negligible effect on the dose 
distribution, relative to water. Measurements performed with the stainless steel backing showed a uniform 
decrease of 4% in absolute dose, relative to measurements made without the stainless steel plaque backing. 
This decrease was observed to be independent of both measurement depth and plaque size. A constant dose 
correction factor of T = 0.96 was used in PS to account for the effect of the stainless steel plaque backing on 
the CAX. The three-dimensional model of the plaque, as well as the dose correction factor resulted in an 
accurate model of the off-axis profiles. Finally, the RADCALC® independent checking program was found 
to agree with PS for a homogeneous water calculation to within 2% on the plaque CAX, and can therefore be 
considered as appropriate for use as an independent checking program for eye plaque treatment times as 
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